GSK Bio
NEWS
Vir Biotechnology and GlaxoSmithKline dosed the first patient last week in a Phase II/III clinical trial of VIR-7831, a fully human monoclonal antibody against COVID-19.
In a regulatory filing with the U.S. Securities and Exchange Commission, Translate Bio indicated that the COVID-19 vaccine it is developing with Sanofi induced an immune response in non-human studies.
Less than one month after GlaxoSmithKline took a 10% stake in CureVac, the Germany-based company raised $213 million in an initial public offering Thursday.
Blenrep is GSK’s second regulatory approval in four months. GlaxoSmithKline is once again making its mark as an oncology-focused pharmaceutical company.
GlaxoSmithKline and Sanofi struck a $2.1 billion deal with the U.S. government’s Operation Warp Speed program to supply an initial 100 million doses of a COVID-19 vaccine candidate under development by the two companies.
Three months after joining forces to develop an adjuvanted vaccine for COVID-19, Sanofi and GlaxoSmithKline reached an agreement with the U.K. government to provide up to 60 million doses of the preventative medication.
The two companies will combine their mRNA research to develop the potential vaccines across a range of infectious disease pathogens.
Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
“We are pleased the committee recognized the potential for belantamab mafodotin to help patients who have relapsed or refractory multiple myeloma, an incurable disease with limited treatment options,” said Axel Hoos, senior vice president and heat of Oncology R&D for GSK.
JOBS
IN THE PRESS